linjc16/ctgov huggingface dataset:
Comparative Results of Maxillary Deficiency Treatment by Tongue Plate and Facemask in Growing Patients

Study Overview
=================
Brief Summary
-----------------
A new appliance will be used to transfer the tongue force during its physiological activity to advance the nasomaxillary complex; this method will be compared with the traditional method which uses a Facemask appliance.

Detailed Description
-----------------
The above method will be compared with traditional one which uses the Facemask in combination with an intra-oral appliance.

Official Title
-----------------
This Study is to Apply the Tongue Force to Correct the Dentofacial Deformities

Conditions
-----------------
Maxillary Deficiency

Intervention / Treatment
-----------------
* Other: Tongue plate
* Other: Facemask


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Growing patients Class III with maxillary deficiency Exclusion Criteria: Previous orthodontic treatment Un cooperative patients

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 14 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A<br> | Other: Tongue plate<br>* A functional appliance use for maxillary protraction.It has two adams clasp and two C clasp to retained the appliance and long palatal plate in the canine area which cages the tongue and transfer the force of the tongue during physiological activity to the upper arch. It has posterior bite plate and middle screw for maxillary expansion.It should be used all the time except meal time and brushing the teeth,the acrylic appliance makes specifically for the patient.<br>* Other names: tongue appliance;|
| Experimental: B<br> | Other: Facemask<br>* An extraoral appliance use for treatment of maxillary deficiency in growing patients.It takes anchorage from chin and forehead, it has removable intraoral appliance with hooks for elastics that exerted a force of 300 gr.It should be used 14 hours a day.<br>* Other names: Reverse pull headgear;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cephalometric angles and clinical features |  | At least 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Tongue plate, Facemask, class III maxillary deficiency, orthodontic angle class three
A Study of ABT-751 in Patients With Non-Small Cell Lung Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with non-small cell lung cancer. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.

Official Title
-----------------
A Phase II Study of ABT-751 in Patients With Non-Small Cell Lung Cancer Refractory to Taxane Regimens

Conditions
-----------------
Non-Small Cell Lung Cancer

Intervention / Treatment
-----------------
* Drug: ABT-751


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Stage IIIB or IV non-small cell lung cancer. Recurrent tumor following treatment with paclitaxel or docetaxel. Able to tolerate normal activities of daily living. Adequate bone marrow, kidney and liver function. Exclusion Criteria Pregnant or breast feeding. Anti-tumor therapy within 4 weeks of the start of ABT-751 administration. CNS metastasis.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: ABT-751|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Objective Response Rate in subjects with NSCLC |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to Tumor Progression (TTP) |  | 1 year | 
| Survival |  | 2 years | 
| Toxicities associated with treatment administration |  | 1 year |
Incidence and Risk Factors of Parastomal Bulging in Patients With Ileostomy or Colostomy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to use routinely-collected health data from registers to examine the incidence of parastomal bulging (PB) at different time points in the first year after surgery for ileostomy or colostomy. Additionally, the purpose is to investigate risk factors for development of PB.

Detailed Description
-----------------
Parastomal bulging (PB) in patients with ileostomy and colostomy in the Capital Region of Denmark up to one year after surgery is the primary outcome in this study. The investigators will use a register-based study design to evaluate routinely-collected health data from the Danish Stoma Database Capital Region (DSDCR). Incidence of PB one year post surgery and at different points of follow-up during the first year will be investigated using survival analysis. Potential risk factors will be investigated controlling for potential confounders. In order to include relevant variables on lifestyle, comorbidity, and physical status, data from the DSDCR will be linked to data from the Danish Anaesthesia Database.

Official Title
-----------------
Incidence and Risk Factors of Parastomal Bulging in Patients With Ileostomy or Colostomy: a Register-based Study

Conditions
-----------------
Colostomy, Ileostomy - Stoma, Enterostomy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject is registered in the Danish Stoma Database Capital Region Is registered as having either ileostomy, jejunostomy, sigmoidostomy, or transversostomy Exclusion Criteria: Patients with urostomy or unknown stoma type
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Ileostomy or colostomy<br>Patients with a ileostomy or colostomy in the Capital Region of Denmark | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with the incidence of parastomal bulging | Parastomal bulging evaluated by stoma care nurses through symptoms, visual inspection, and stomal exploration. Parastomal bulging is evaluated at scheduled visits at stoma care clinics on postoperative days 30, 90, 180, and 365, and at any additional visits inbetween. | Up to 1 year after primary surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
parastomal bulging, peristomal bulging, ileostomy, colostomy, enterostomy, incidence, risk factor
Multicenter Prospective Evaluation of the Incidence and Serotyes of Invasive Pneumoccocal Disease (IPD) Among Children Below 5 Years

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to identify the S. pneumoniae serotypes strains and to determine antibiotic susceptibility.

Official Title
-----------------
Serotyping of Pneumococci

Conditions
-----------------
Pneumococcal Disease

Intervention / Treatment
-----------------
* Biological: pneumococcal conjugate vaccine(prevenar)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age less than 5 years Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 3 Weeks
Maximum Age: 5 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: pneumococcal conjugate vaccine(prevenar)|to see the vaccine impact on pneumococcal diseases|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence and serotypes of invasive pneumococcal dis. |  | 6-8 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Antibiotic susceptibility |  | 6-8 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Laboratory based study, antibiotic susceptibilty, invasive strains
Evaluation of Three SS-OCT and One PCI Optical Biometers in Eyes With Dense Cataract

Study Overview
=================
Brief Summary
-----------------
To describe and compare the acquisition rate between different biometers in eyes with advanced cataracts

Detailed Description
-----------------
To describe and compare the acquisition rate between different biometers in eyes with advanced cataracts

Official Title
-----------------
Evaluation of Three SS-OCT and One PCI Optical Biometers in Eyes With Dense Cataract: Benefit of Use of the Enhance Retina Visualization Mode

Conditions
-----------------
Optical Biometer, Cataracts

Intervention / Treatment
-----------------
* Diagnostic Test: Ocular biometry


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: LOCS III cataract classification with a grade of ≥3 for nuclear, cortical or posterior subcapsular. DLI index, from the ITrace device, should be ≤ 5. Exclusion Criteria: Previous continuous contact lens wear Ocular trauma Intraocular lens surgery Poor fixation Corneal disease (i.e. keratoconus)
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Ocular biometry|Biometry using swept-source OCT Argos, swept-source OCT IOLMaster 700, swept-source OCT Anterion, PCI Pentacam AXL, OcuScan RxP and Itrace measurement|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To describe and compare the acquisition rate between different biometers in eyes To describe and compare the acquisition success rate between different biometers in eyes with advanced cataracts | Acquision succes rate is indicated by a percentage, from 0% to 100%. The biometer can obtain (success) or not (failure) the measurement. This value will be indicated for each biometer. | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To describe the correlation of success rate and Dysfunctional Lens Index (DLI, iTrace) |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
optical biometer, cataracts
Hemp Oil + User Experience Study

Study Overview
=================
Brief Summary
-----------------
Presented as an online survey, this study seeks to better understand how Thorne customers are using and experiencing the new Hemp Oil + product and how they feel it compares in the marketplace. Hemp Oil + is a combination product with a proprietary blend of hemp, clove, black pepper, hops, and rosemary extracts. People who have independently elected to purchase and use Hemp Oil + before the study starts will be invited to voluntarily participate. If they meet study requirements and give consent they will answer questions online about their experience with Hemp Oil +. Questions address general demographics and wellness, general impressions of the product, how it compares to other products, and any effect it has had on their gastrointestinal health, physical discomfort, sleep, and mood. The survey is expected to take 15-30 min of participant time. Data will be analyzed to determine whether the customer experience with Hemp Oil + is as favorable as it seems from anecdotal reports. Analysis will also be conducted to find patterns that can inform future studies, marketing, and customer education efforts.

Official Title
-----------------
Hemp Oil + User Experience Study: A Retrospective, Non-Interventional Study to Assess Consumer Experience and the Impact of Hemp Oil + on Quality of Life

Conditions
-----------------
General Wellbeing, Gastrointestinal Health, Physical Discomfort, Sleep, Mood

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Has personally used at least one bottle (30 gelcaps) of Hemp Oil + Provides consent to participate in the study Exclusion Criteria: Cannot access or use the electronic survey for any reason Was pregnant or nursing when taking Hemp Oil + Is a Thorne employee not willing to participate without compensation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess impact to overall quality of life (QoL) after taking Hemp Oil + | Questionnaire gathering data from the past 30 or more days | 1 Day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess impact to specific QoL factors - GI health, mood, sleep, physical discomfort - after taking Hemp Oil + | Questionnaire gathering data from the past 30 or more days | 1 Day | 
| Gain insight into user perspective on product quality, efficacy, and rationale for continuing/discontinuing use | Questionnaire gathering data from the past 30 or more days | 1 Day |
Effect of 1.8-mm Steep-axis Clear Corneal Incision on the Posterior Corneal Astigmatism in Candidates for Toric IOL Implantation

Study Overview
=================
Brief Summary
-----------------
we aimed to analyze the effects of cataract surgery using a 1.8-mm steep-axis clear corneal incision (CCI) on the posterior corneal surfaces based on the keratometry from the rotating Scheimpflug imaging device (Pentacam HR) in candidates for toric intraocular lens (IOL) implantation

Detailed Description
-----------------
Preoperative and at least 1-month postoperative data measured by Pentacam HR were collected in patients for toric IOL implantation. Surgically induced astigmatism on the posterior cornea (P-SIA) was calculated based on the preoperative and postoperative keratometric data, and the related factors of P-SIA were analyzed.

Official Title
-----------------
Effect of 1.8-mm Steep-axis Clear Corneal Incision on the Posterior Corneal Astigmatism in Candidates for Toric IOL Implantation

Conditions
-----------------
Cataract

Intervention / Treatment
-----------------
* Behavioral: astigmatism


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients aged at least 45 years old who were scheduled for cataract surgery; (2) regular corneal astigmatism ≥ 1.0 D; (3) the imaging quality parameter (QS) of Pentacam HR was OK; and (4) follow-up time ≥1.0 month. Exclusion Criteria:(1) irregular corneal astigmatism; (2) corneal scar, corneal degeneration, pterygium invading the optic zone; (3) corneal endothelium count<1,000/mm2, corneal endothelial dystrophy, iritis, glaucoma and retinal disease; (4) history of eye surgery, such as corneal refractive surgery, corneal transplantation and retinal surgery; (5) the main incision was expanded or sutures were used during surgery; and (6) some postoperative complications, such as persistent corneal edema, Descemet's membrane detachment and poor wound healing, and any others that might affect the measurement results of the Pentacam HR during the follow-up period. -

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: astigmatism|astigamatism at least 1 month after the cataract surgery|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| corneal astigmatism | postoperative anterior, posterior and total corneal astigmatism | post 1 month |
Impact of a Training in Therapeutic Education on the Relation Between Care Givers and Their Patients

Study Overview
=================
Brief Summary
-----------------
This study aims to describe the impact of a training in therapeutic education on the relation between a caregiver and his/her patients. Subjects are recruited among health professionals attending a training in therapeutic education. Then they are asked to identify up to 5 of their patients to be contacted by the researcher for an interview. Individual semi-structured interviews are conducted with 20 duo caregivers / patients before the training, 1 month and 6 months after the training.

Official Title
-----------------
Impact of a Training in Therapeutic Education on the Relation Between Care Givers and Their Patients

Conditions
-----------------
Cancer of Liver, Diabetes

Intervention / Treatment
-----------------
* Other: Semi-Structured interviews


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Informed consent to participate to 3 interviews Exclusion Criteria: Not fluent French speaker Patient under guardianship

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Health Professionals<br>Health Professionals attending a training in therapeutic education | Other: Semi-Structured interviews<br>* individual semi-structured interviews<br>|
| Patients<br>Patients of the health Professionals recruited for the study | Other: Semi-Structured interviews<br>* individual semi-structured interviews<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Semi-Structured interviews | Qualitative analysis - theorical saturation | 9 months |
Long-term Extension Study to Evaluate the Safety of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to demonstrate that dutogliptin/PHX1149T is safe and tolerable.

Official Title
-----------------
An Open Label, Multi-Center, Long-Term Follow-up Study to Evaluate the Safety of PHX1149T in Subjects With Type 2 Diabetes Mellitus - Extension to Protocol PHX1149-PROT202

Conditions
-----------------
Type 2 Diabetes Mellitus

Intervention / Treatment
-----------------
* Drug: dutogliptin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Completed Visit 7/Day 98 of the core protocol PHX1149-PROT202 Current treatment of Type 2 diabetes mellitus in accordance with product labeling with metformin, or thiazolidinedione (TZD), or metformin + TZD Exclusion Criteria: Inadequately controlled Type 2 diabetes mellitus with need for therapy with insulin

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: dutogliptin|400 mg QD|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To demonstrate safety and tolerability of dutogliptin/PHX1149T as assessed by vital signs, adverse event reporting, and routine clinical laboratory assessments |  | 104 weeks | 
| To demonstrate safety and tolerability of dutogliptin/PHX1149Tas assessed by vital signs, adverse event reporting, and routine clinical laboratory assessments |  | 208 weeks (U.S. only) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To demonstrate maintenance or lowering of HbA1c and fasting blood glucose |  | 104 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
diabetes, DPP4 inhibitor, dutogliptin, PHX1149